Sam Brusco, Associate Editor01.31.23
Axonics, a company developing products for bladder and bowel dysfunction, has gained U.S. Food and Drug Administration (FDA) approval for its fourth-generation rechargeable sacral neuromodulation system.
The Axonics R20 neurostimulator can have a functional life in the body for at least 20 years, and reduces the frequency of recharging the implanted device to once every six to 10 months for an hour. This compares to the third-generation’s recharge interval of once a month for an hour.
The R20 neurostimulator has the same 5cc form factor as the R15 and is paired with the same tined lead and intuitive patient remote control. The company plans to launch the product in the U.S. in March.
“Delivering a superior patient experience has been at the forefront of our sacral neuromodulation development efforts,” John Woock, Ph.D., executive VP, chief marketing and strategy officer of Axonics, told the press. “Patients with overactive bladder tell us that first and foremost, they value efficacy and a long-lived solution to address their chronic condition. The Axonics R20, which requires recharging just twice per year, represents another significant breakthrough for rechargeable neuromodulation devices and underscores our commitment to continuous innovation. We are confident that Axonics’ keen focus on the incontinence patient population and increasing public awareness of sacral neuromodulation has the potential to drive significant market expansion in the years ahead.”
The Axonics R20 neurostimulator can have a functional life in the body for at least 20 years, and reduces the frequency of recharging the implanted device to once every six to 10 months for an hour. This compares to the third-generation’s recharge interval of once a month for an hour.
The R20 neurostimulator has the same 5cc form factor as the R15 and is paired with the same tined lead and intuitive patient remote control. The company plans to launch the product in the U.S. in March.
“Delivering a superior patient experience has been at the forefront of our sacral neuromodulation development efforts,” John Woock, Ph.D., executive VP, chief marketing and strategy officer of Axonics, told the press. “Patients with overactive bladder tell us that first and foremost, they value efficacy and a long-lived solution to address their chronic condition. The Axonics R20, which requires recharging just twice per year, represents another significant breakthrough for rechargeable neuromodulation devices and underscores our commitment to continuous innovation. We are confident that Axonics’ keen focus on the incontinence patient population and increasing public awareness of sacral neuromodulation has the potential to drive significant market expansion in the years ahead.”